Peringatan Keamanan

There is no information available regarding the LD50 of secukinumab. In clinical trials, doses up to 30 mg/kg intravenously have been administered without dose-limiting toxicity. In the event of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately. L39600

Secukinumab

DB09029

biotech approved

Deskripsi

Secukinumab is a fully human monoclonal IgG1/? antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis.L39600 By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.A249840 Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015).A249805 It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.L39600,L42280,L48771

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life ranged from 22 to 31 days in plaque psoriasis subjects following intravenous and subcutaneous administration across all psoriasis trials.[L39600] The mean elimination half-life was 27 days.[L42280]
Volume Distribusi The mean volume of distribution during the terminal phase (V<sub>z</sub>) ranged from 7.10 to 8.60 L in plaque psoriasis subjects who received secukinumab intravenously.[L39600] These values suggest that secukinumab undergoes limited distribution to peripheral compartments.[L42280] The volume of distribution increases with body weight. Following subcutaneous administration of a single 300 mg dose, drug concentrations in interstitial fluid in lesional and non-lesional skin of plaque psoriasis subjects ranged from 27% to 40% of those in serum at one and two weeks.[L39600]
Klirens (Clearance) The mean systemic clearance (CL) ranged from 0.14 L/day to 0.22 L/day.[L39600] Clearance of secukinumab is dose- and time-independent,[A249805,L42280] and is expected to increase with body weight.[L39600]

Absorpsi

Following a single subcutaneous dose of either 150 mg - which is one-half the recommended dose - in patients with plaque psoriasis, the mean Cmax and serum trough concentrations were 13.7 ± 4.8 mcg/mL and 22.8 ± 10.2 mcg/mL, respectively. Following administration of 300 mg, the mean Cmax and serum trough concentrations were 27.3 ± 9.5 mcg/mL and 45.4 ± 21.2 mcg/mL, respectively.L39600 Following subcutaneous injection, the Cmax is reached in five to six days.A249805 Steady-state concentrations were achieved by week 24 following the every 4-week dosing regimens. In healthy subjects and subjects with plaque psoriasis, bioavailability ranged from 55% to 77% following subcutaneous administration.L39600

Metabolisme

Secukinumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.L39600

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1334 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Secukinumab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Secukinumab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Secukinumab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Secukinumab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Secukinumab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Secukinumab.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Secukinumab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Secukinumab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Secukinumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Secukinumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Secukinumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Secukinumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Secukinumab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Secukinumab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Secukinumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Secukinumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Secukinumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Secukinumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Secukinumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Secukinumab.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Secukinumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Secukinumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Secukinumab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Secukinumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Secukinumab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Secukinumab.
Cladribine Secukinumab may increase the immunosuppressive activities of Cladribine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Secukinumab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Secukinumab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Secukinumab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Secukinumab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Secukinumab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Secukinumab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Secukinumab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Secukinumab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Secukinumab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Secukinumab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Secukinumab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Secukinumab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Secukinumab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Secukinumab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Secukinumab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Secukinumab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Secukinumab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Secukinumab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Secukinumab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Secukinumab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Secukinumab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Secukinumab.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Secukinumab.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Secukinumab.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Secukinumab.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Secukinumab.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Secukinumab.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Secukinumab.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Secukinumab.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Secukinumab.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Secukinumab.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Secukinumab.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Secukinumab.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Secukinumab.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Secukinumab.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Secukinumab.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Secukinumab.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Secukinumab.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Secukinumab.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Secukinumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Secukinumab.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Secukinumab.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Secukinumab.
Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Secukinumab.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Secukinumab.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Secukinumab.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Secukinumab.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Secukinumab.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Secukinumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Secukinumab.
Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa is combined with Secukinumab.
Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Secukinumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Secukinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Secukinumab.
Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Secukinumab.
Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Secukinumab.
Rilonacept The risk or severity of adverse effects can be increased when Rilonacept is combined with Secukinumab.
Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Secukinumab.
Abetimus The risk or severity of adverse effects can be increased when Abetimus is combined with Secukinumab.
Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Secukinumab.
Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Secukinumab.
Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Secukinumab.
Wortmannin The risk or severity of adverse effects can be increased when Wortmannin is combined with Secukinumab.
Eribulin The risk or severity of adverse effects can be increased when Eribulin is combined with Secukinumab.
Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Secukinumab.
Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Secukinumab.
Carfilzomib The risk or severity of adverse effects can be increased when Carfilzomib is combined with Secukinumab.
Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Secukinumab.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Secukinumab.
Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Secukinumab.
Vedolizumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Vedolizumab.

Target Protein

Interleukin-17A IL17A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 26647300
    Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B: Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol. 2016 Feb;9(2):187-202. doi: 10.1586/17512433.2016.1129894.
  • PMID: 26664127
    Roman M, Madkan VK, Chiu MW: Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015 Dec 2;11:1767-77. doi: 10.2147/TCRM.S79053. eCollection 2015.
  • PMID: 25648267
    Sanford M, McKeage K: Secukinumab: first global approval. Drugs. 2015 Feb;75(3):329-38. doi: 10.1007/s40265-015-0359-0.
  • PMID: 30725776
    Aboobacker S, Kurn H, Al Aboud AM: Secukinumab .
  • PMID: 29344327
    Frieder J, Kivelevitch D, Menter A: Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16.

Contoh Produk & Brand

Produk: 23 • International brands: 0
Produk
  • Cosentyx
    Injection • 150 mg/1mL • Subcutaneous • US • Approved
  • Cosentyx
    Injection • 75 mg/0.5mL • Subcutaneous • US • Approved
  • Cosentyx
    Solution • 150 mg / mL • Subcutaneous • Canada • Approved
  • Cosentyx
    Powder, for solution • 150 mg / mL • Subcutaneous • Canada • Approved
  • Cosentyx
    Solution • 75 mg / 0.5 mL • Subcutaneous • Canada • Approved
  • Cosentyx
    Solution • 300 mg / 2 mL • Subcutaneous • Canada • Approved
  • Cosentyx
    Solution • 300 mg / 2 mL • Subcutaneous • Canada • Approved
  • Cosentyx
    Injection • 300 mg/2mL • Subcutaneous • US • Approved
Menampilkan 8 dari 23 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul